Citations

Clear

623 citation(s) found for "Torres, V".

Pruritic eruption associated with rheumatoid arthritis: rheumatoid neutrophilic dermatitis
Aristizabal, Miguel, Sluzevich, Jason C. , Singer, Elisha, Torres, Miguel A. Aristizabal , Aristizabal, Miguel A , Sluzevich, Jason C

Mayo Clinic

BMJ Case Reports | January 14, 2025 | Volume: 18 | Issue: 1 | Pages: e263151

10.1136/bcr-2024-263151 | PMID 39809492 Get It

A field resource for the glioma cerebrospinal fluid proteome: Impacts of resection and location on biomarker discovery
Riviere-Cazaux, Cécile , Warrington, Arthur E. , Hoplin, Matthew D. , Andersen, Katherine M., Malik, Noor , Palmer, Elizabeth, Dasari, Surendra , Munoz-Casabella, Amanda , Ikram, Samar, Jusué-Torres, Ignacio , Meyer, Fredric B. , Kizilbash, Sani H. , Campian, Jian , Palmer, Elizabeth A, Carlstrom, Lucas P. , Sarkaria, Jann N , Van Gompel, Jamie J , Kizilbash, Sani H , Jusue-Torres, Ignacio , Malik, Noor , Michor, Franziska , Ghadimi, Keyvan , Himes, Benjamin , Sarkaria, Jann N. , Gompel, Jamie J. Van , Sener, Uğur , Parney, Ian F. , Burns, Terry C.

Mayo Clinic

Neuro-Oncology | December 27, 2024 | Volume: 27 | Issue: 4 | Pages: 948-962

10.1093/neuonc/noae277 | PMID 39786485 Get It

Abstract Background While serial sampling of glioma tissue is rarely performed prior to recurrence, cerebrospinal fluid (CSF) is an underutilized longitudinal source of candidate glioma biomarkers for understanding therapeutic impacts. However, the impact of key variables to consider in longitudinal CSF samples for monitoring biomarker discovery, including anatomical location and post-surgical changes, remains unknown. Methods Aptamer-based proteomics was performed on 147 CSF samples from 74 patients; 71 of whom had grade 2–4 astrocytomas or grade 2–3 oligodendrogliomas. This included pre- versus post-resection intracranial CSF samples obtained at early (1–16 days; n = 20 patients) or delayed (86–153 days; n = 11 patients) time points for patients with glioma. Paired lumbar versus intracranial glioma CSF samples were also obtained (n = 14 patients). Results Significant differences were identified in the CSF proteome between lumbar, subarachnoid, and ventricular CSF in patients with gliomas. Importantly, we found that resection had a significant, evolving longitudinal impact on the CSF proteome, with distinct sets of proteins present at different time points since resection. Our analysis of serial intracranial CSF samples suggests the early potential for disease monitoring and evaluation of pharmacodynamic impact of targeted therapies, such as bevacizumab and immunotherapies. Conclusions The intracranial glioma CSF proteome serves as a rich and dynamic reservoir of potential biomarkers that can be used to evaluate the effects of resection and other therapies over time. All data within this study, including detailed individual clinical annotations, are shared as a resource for the neuro-oncology community to collectively address these unanswered questions and further understand glioma biology through CSF proteomics.
DEK::AFF2 Fusion Sinonasal and Skull Base Nonkeratinizing Squamous Cell Carcinoma
Hart, Stephanie A , Mikula, Michael W. , Amin, Sara E. , Saluja, Karan , Chen, Y., David, Stephanie N., Dupont, William D., Plummer, W. Dale, Ferrer, Karen, Geromes, Ariana, Hsieh, Min-Shu, Kuo, Ying‐Ju , Sasaki, Eiichi , Shi, Qiuying , Truong, Tra , Lewis, James S. , Lewis, James S , Hang, Jen‐Fan , Chernock, Rebecca , Rooper, Lisa M. , Bishop, Justin A. , Cipriani, Nicole A. , Hsieh, Min‐Shu , Hernandez‐Prera, Juan C. , Torres, Jaylou M. Velez

Mayo Clinic

American Journal of Surgical Pathology | December 25, 2024 | Volume: 49 | Issue: 2 | Pages: 130-137

10.1097/pas.0000000000002335 | PMID 39719672 Get It

DEK::AFF2 fusion nonkeratinizing squamous cell carcinoma (NKSCC) is an emerging entity in the sinonasal tract, temporal bone, and skull base. However, the clinical behavior of these tumors has not been well studied. Here, we report the largest cohort of DEK::AFF2 carcinomas to determine if morphology, mitotic rate, and/or Ki-67 IHC are associated with patient outcomes, including a comparison with high-risk human papillomavirus (HPV)-associated and independent patients. We solicited cases of molecularly or AFF2 immunohistochemistry (IHC) proven DEK::AFF2 SCC from surgical pathologists to collect patient demographic, clinical, and outcome data. Using representative H&E slides, we characterized the morphology and counted mitoses. Ki-67 immunohistochemistry was performed. We also compared the DEK::AFF2 survival rates to those in a cohort of AFF2 IHC-negative HPV-associated and HPV-independent SCC. DEK::AFF2 carcinomas most commonly arose in the nasal cavity (13/30, 43%), and the average number of recurrences was 1.8 (range: 0 to 10). At the last follow-up, most patients were disease free (19/30, 63%) or were alive with disease (9/30, 30%). There was an average mitotic rate of 2 per 2 mm2 (range: 0 to 9) and Ki-67 proliferation rate of 26% (range: 3% to 60%). Local recurrence was common, but morphology, mitotic activity, and Ki-67 index were not associated with recurrence or survival. On Kaplan-Meier survival analysis, DEK::AFF2 patients had lower disease-free survival but otherwise had similar outcomes to conventional SCC patients. Our multi-institutional study shows that local recurrence is common in DEK::AFF2 fusion nonkeratinizing SCC patients, but patients have survival rates similar to conventional SCC. Despite showing a range of different features and proliferation rates, traditional grading by morphology, mitotic rate, and/or Ki-67 activity does not seem to be predictive of outcome.
Longitudinal Glioma Monitoring via Cerebrospinal Fluid Cell-Free DNA
Riviere-Cazaux, Cécile , Dong, Xiaoxi , Mo, Wei , Kumar, Rahul , Dai, Chao , Carlstrom, Lucas P. , Munoz-Casabella, Amanda , Nesvick, Cody L. , Andersen, Katherine M., Hoplin, Matthew D. , Canaday, Nicholas, Jusué-Torres, Ignacio , Malik, Noor , Campian, Jian L., Ruff, Michael W. , Uhm, Joon H. , Eckel‐Passow, Jeanette E. , Kizilbash, Sani H. , Warrington, Arthur E. , Jenkins, Robert B. , Du, Pan , Jia, Shidong , Ghadimi, Keyvan , Nesvick, Cody L , Andersen, Katherine M , Hoplin, Matthew D , Canaday, Nicholas , Jusue-Torres, Ignacio , Malik, Noor , Campian, Jian L , Ruff, Michael W , Uhm, Joon H , Eckel-Passow, Jeanette E , Kaufmann, Timothy J , Routman, David M , Kizilbash, Sani H , Sener, Ugur , Warrington, Arthur E , Jenkins, RB , Du, Pan , Jia, Shidong , Burns, Terry C , Kumar, Rahul , Kaufmann, Timothy J. , Routman, David M. , Sener, Uğur , Burns, Terry C.

Mayo Clinic

Clinical Cancer Research | December 23, 2024 | Volume: 31 | Issue: 5 | Pages: 881-889

10.1158/1078-0432.ccr-24-1814 | PMID 39715486 Get It

Abstract Purpose: Current methods for glioma response assessment are limited. This study aimed to assess the technical and clinical feasibility of molecular profiling using longitudinal intracranial cerebrospinal fluid (CSF) from patients with gliomas. Experimental Design: Adults with gliomas underwent longitudinal intracranial CSF collection via Ommaya reservoirs or ventriculoperitoneal shunts. Cell-free DNA (cfDNA) was extracted and analyzed using PredicineCARE for cancer variant profiling and/or PredicineSCORE for low-pass whole-genome sequencing. Results: Five patients (two females and three males; median age, 40 years; range, 32–64 years) underwent longitudinal intracranial CSF collection via Ommaya reservoirs (n = 4) or ventriculoperitoneal shunts (n = 1). In total, 47 CSF samples were obtained (median volume, 4.00 mL; 0.5–5 mL). Forty-one samples (87.2%) yielded sufficient cfDNA for testing. Patient-specific tumor-associated variant allelic frequencies (VAF), and thus tumor fraction, decreased in pre- versus postchemoradiation samples, including through pseudoprogression. These also increased with radiographic progression in three patients, although identifying the time of definitive disease progression from MRIs was a significant limitation. In two patients with isocitrate dehydrogenase (IDH)–mutant gliomas, decreasing IDH1 VAF after resection and chemoradiation correlated with decreased CSF D-2-hydroxyglutarate levels (0.64× and 0.62×, respectively, for the first patient and 0.01× and 0.07× for the other patient), although D-2-hydroxyglutarate and IDH1 VAF were not concordant in one patient thereafter. Moreover, the copy-number burden decreased below the limit of quantification during treatment and increased above the limit at progression. Conclusions: Longitudinal intracranial CSF cfDNA can be obtained in patients with gliomas during their disease course. However, before deploying this technique, numerous questions and challenges should be answered.
Cellulite & Skin Tightening: A Review of Pathophysiology and Topical Treatment
Castellanos‐García, Isabella, Ramírez‐Zuluaga, Luisa Valentina, Páez‐Cárdenas, Laura Sofia, Villalba‐Moreno, Dennys Lintsay, Caicedo‐León, María Daniela, Singer, Elisha, Bruce, Alison J., Aristizabal, Miguel, Torres, Miguel A. Aristizabal , Aristizabal, Miguel A , Pincelli, Thaís

Mayo Clinic

Dermatological Reviews | December 19, 2024 | Volume: 5 | Issue: 6 | Pages: No page available

10.1002/der2.70011 Get It

ABSTRACTBackgroundCellulite is a localized skin condition that affects many women, particularly after puberty. It results from a complex interplay of several factors that lead to the characteristic dimpled appearance of the skin. Cellulite may cause psychological stress and negatively impact quality of life. Additionally, body skin laxity may further exacerbate cosmetic concerns in these patients. Consequently, multiple therapeutic options, including topical treatments, have been explored to address both cellulite and skin laxity.ObjectivesTo review the pathophysiology of cellulite and skin laxity, as well as topical skincare options for their management.MethodsA literature search from 2000 to 2024 was conducted using the databases PubMed, EBSCOhost, Scopus, and Google Scholar, with the key terms “cellulite,” “cellulite management,” “cellulite topical treatment,” “skin sagging,” “skin laxity,” and “loose skin.” The search included clinical trials, observational studies, book chapters, and review articles in English and Spanish.ResultsThe pathophysiologic mechanisms underlying cellulite involve a combination of histological, hormonal, genetic, and lifestyle factors. Several topical agents, including retinoids and methylxanthines, have shown potential in improving the cosmetic appearance of cellulite and may contribute to localized fat reduction. Emerging botanical extracts hold promise as topical treatments for cellulite and skin tightening.ConclusionsCellulite and skin laxity are prevalent cosmetic concerns with multifactorial and complex pathophysiologic origins. Topical treatments for cellulite and skin tightening require further investigation. Although some studies have demonstrated positive outcomes with skincare products and topicals, robust evidence and studies with extended follow‐up are still lacking. Additional research is necessary to evaluate the long‐term efficacy of topical treatments as standalone therapies for cellulite and skin tightening.
Consensus Recommendations for Studies of Outflow Facility and Intraocular Pressure Regulation Using Ex Vivo Perfusion Approaches
Acott, Ted S. , Fautsch, Michael P. , Mao, Weiming , Huang, Alex S. , Kelley, Mary J. , Aga, Mini , Borrás, Terete, Bovenkamp, Diane E. , Chowdhury, Uttio Roy, Clark, Abbot F. , Dibas, Mohammed, Elliott, Michael H. , Faralli, Jennifer A., Gong, Haiyan , Kaufman, Paul L., Keller, Kate E. , Kuehn, Markus H. , Li, Hoi Lam, Lin, Shan C. , Liu, Yutao , McDonnell, Fiona , McDowell, Colleen M. , Mzyk, Philip , Nair, K. Saidas , Overby, Darryl R. , Peters, Donna M. , Raghunathan, VijayKrishna, Rao, Ponugoti Vasantha , Roddy, Gavin W. , Sharif, Najam A. , Shim, Myoung Sup , Sun, Yang , Thomson, Benjamin R. , Willoughby, Colin E. , Freddo, Thomas F., Fuchshofer, Rudolf , Hill, Kamisha R. , Karimi, Alireza , Kizhatil, Krishnakumar , Kopcyznski, Casey C., Patel, Gaurang , Pattabiraman, Padmanabhan P. , Prasanna, Ganesh , Samples, E. Griffen, Samples, John R., Steel, Cynthia, Subramanian, Preeti, Sugali, Chenna Kesavulu , Sherwood, Joseph M. , Wong, Cydney A. , Zode, Gulab , White, Elizabeth , Liu, Yutao , Ethier, C. Ross , Bhattacharya, Sanjoy K. , Du, Yiqin , Herberg, Samuel , Johnstone, Murray , Kelly, Ruth A. , Križaj, David , Lieberman, Raquel L. , McLellan, Gillian J. , Raghunathan, VijayKrishna, Rao, Ponugoti Vasantha , Toris, Carol B. , Zhang, Hao F. , Liton, Paloma B. , Peng, Michael , Reina‐Torres, Ester , Strohmaier, Clemens , Youngblood, Hannah A. , Stamer, William Daniel

Mayo Clinic

Investigative Ophthalmology & Visual Science | December 18, 2024 | Volume: 65 | Issue: 14 | Pages: 32

10.1167/iovs.65.14.32 | PMID 39693082 Get It

Association between Locoregional Failure and NFE2L2/KEAP1/CUL3 Mutations in NRG/RTOG 9512: A Randomized Trial of Radiation Fractionation in T2N0 Glottic Cancer
Guan, Li , Torres‐Saavedra, Pedro A. , Zhao, Xiaobei , Major, Michael B. , Holmes, Brittany , Nguyen, Ngan K. , Kumaravelu, Parasakthy , Hodge, Tim , Diehn, Maximilian , Zevallos, Jose P. , Emami, Bahman, Hayward, Michele C. , Sagar, Stephen M. , Morrison, William H. , Schultz, Christopher J. , Jones, Christopher U. , Galloway, Thomas J. , Yom, Sue S. , Kudrimoti, Mahesh , Kim, Harold E., Harris, Jonathan , Le, Quynh‐Thu , Holmes, Brittany J , Zevallos, Jose , Holsinger, F Chris , Emami, Bahman , Jordan, Richard C , Hayward, Michele C , Sagar, Stephen M , Morrison, William , Schultz, Christopher , Caudell, Jimmy J , Jones, Christopher U , Bratman, Scott V , Galloway, Thomas J , Ma, Daniel , Yom, Sue S , Kudrimoti, Mahesh , Kim, Harold E , Harris, Jonathan , Le, Quynh-Thu , Hayes, D Neil , Diehn, Maximillian , Holsinger, F. Christopher , Daniel, J.

Mayo Clinic

Clinical Cancer Research | December 10, 2024 | Volume: 31 | Issue: 9 | Pages: 1615-1624

10.1158/1078-0432.ccr-24-2334 | PMID 39656603 Get It

Abstract Purpose: NFE2L2/KEAP1/CUL3 mutations have been validated for radioresistance in cell-based assays and animal models. However, clinical validation of these biomarkers has been challenging because of multimodality treatment regimens. This study aims to investigate the association between NFE2L2/KEAP1/CUL3 mutations and patient outcomes, including local failure, locoregional failure, disease-free survival (DFS), and overall survival, using samples from a phase III trial in which patients were treated with radiation monotherapy at two controlled doses. Patients and Methods: We investigated NFE2L2/KEAP1/CUL3 mutations in 250 randomized patients with T2N0 glottic squamous cell carcinoma receiving definitive radiotherapy in the NRG/RTOG 9512 trial. A total of 119 patients had available biospecimens that were subjected to amplicon-based next-generation sequencing to assess for the presence of NFE2L2/KEAP1/CUL3 mutations without regard to outcomes. Mutations in NFE2L2/KEAP1/CUL3 were assessed blinded to clinical outcomes. Cox models (two-sided α = 0.05) were used to evaluate the association with clinical outcomes, performed by an independent statistical team. Results: Nineteen of 119 patients (16.0%) had NFE2L2/KEAP1/CUL3 mutations. Patient, treatment, and tumor characteristics were similar between those with and without mutations. Patients with mutation compared with those without had significantly more local failure [HR = 3.50; 95% confidence interval (CI), 1.56–7.89; P = 0.0025] and locoregional failure (HR = 3.80; 95% CI, 1.80–8.03; P = 0.0005). DFS was significantly worse for the mutated compared with the nonmutated group in the first 2 years (HR = 2.88; 95% CI, 1.46–5.66; P = 0.0022). The median DFS was shorter in the mutation group (10.3 months) versus those with intact NFE2L2/KEAP1/CUL3 (4.2 years). Conclusions: NFE2L2/KEAP1/CUL3 mutations may predict radiation treatment failure in T2N0 glottic cancer. See related commentary by Rao, p. 1563
Glioblastoma and its interaction with neurogenesis
Rodríguez-Mendoza, B, Figueroa-Gonzalez, Almaris, Cano-Herrera, Gabriela , Gutierrez-Rosas, L E, Romero-Torres, C I, Victoria-Garcia, Luis Octavio , Gonzalez-Castillo, P, Guerrero‐Cazares, Hugo , Ibarra, Antonio , Guerrero-Cazares, Hugo , Gutierrez-Rosas, Luis Enrique

Mayo Clinic

Revista de Neurología | November 29, 2024 | Volume: 79 | Issue: 10 | Pages: No page available

10.33588/rn.7910.2024226 | PMID 39540380 Get It

Glioblastoma (GBM) is the most frequent and aggressive malignant primary tumor of the central nervous system in adults, with an incidence of 3.23 per 100,000 people. Despite the existence of various therapeutic approaches, the absence of a cure and the unfavorable prognosis persist for this neoplasm, with a median survival of approximately 8-15 months and a 5-year survival rate of 6.9%. In this review, we address the epidemiology, histopathology, molecular characteristics, and treatment of GBM. We highlight the relationship of GBM with the microenvironment in the lateral ventricle wall and the cerebrospinal fluid. The location of GBM in this region results in more aggressive tumors and shorter life expectancy for patients. Understanding the malignancy mechanisms that hinder remission, treatment, and positive prognosis opens the possibility of improving diagnostic and therapeutic interventions against GBM.
Mission and Future Plans for the Autosomal Dominant Polycystic Kidney Disease Centers of Excellence Program
Hoover, Elise , Cambareri, Heidi, Chapman, Arlene B., Chebib, Fouad T. , Moore, Savanna, Perrone, Ronald D. , Garimella, Pranav S , Torres, Vicente E , Chebib, Fouad T , Garimella, Pranav S.

Mayo Clinic

Kidney360 | November 19, 2024 | Volume: 6 | Issue: 1 | Pages: 159-166

10.34067/kid.0000000652 | PMID 39560608 Get It

The Autosomal Dominant Polycystic Kidney Disease (ADPKD) Centers of Excellence (COE) Program, launched by the Polycystic Kidney Disease Foundation in 2022, aims to bridge the gap in specialized care for individuals with ADPKD. This program seeks to enhance the availability of specialized clinicians and simplify the process for patients seeking expert care. It is founded on three pillars: improving care for all individuals with ADPKD, educating and empowering the community, and advancing polycystic kidney disease research. The program draws inspiration from successful models in other diseases, such as cystic fibrosis and muscular dystrophy, which have demonstrated the effectiveness of standardized care centers in improving patient outcomes. Patient and clinician stakeholder interviews have identified key areas where a national program could make a significant effect, including the need for a core care team with defined referral processes, mentorship and shared care models, patient navigation services, and education around expert consensus and care guidelines. The program introduces two designations to accommodate diverse care settings and enhance patient access to specialists: COE and Partner Clinic. The Partner Clinic designation ensures that patients in smaller community practices have access to specialized care through mentorship and guidance from experts at COE. The program also emphasizes the importance of specialized services, especially in underserved communities experiencing health disparities, to manage the complexities of ADPKD care. Patient focus groups have highlighted the need for care navigation services, centralized sources of knowledge, and access to local care. The program aims to address these needs by providing a structured framework for care coordination, enhancing patient self-advocacy, and improving overall outcomes for individuals with ADPKD. Key Points The Autosomal Dominant Polycystic Kidney Disease Centers of Excellence Program aims to improve specialized care for autosomal dominant polycystic kidney disease patients. It introduces two designations to accommodate diverse care settings and enhance patient access to specialists: Center of Excellence and Partner Clinic. The program draws inspiration from successful models in other diseases, such as cystic fibrosis and muscular dystrophy, which have demonstrated the effectiveness of standardized care centers in improving patient outcomes. Key needs and programmatic goals identified through patient and clinician stakeholder interviews include establishing a core care team with defined referral processes, implementing mentorship and shared care models, providing patient navigation services, and offering education on expert consensus and care guidelines.
Evaluating the metformin use on type 2 diabetes prevention in high-risk populations in primary care
Ramírez-Torres, Andony I., Ruiz-Hernández, Fernando G. , Omaña, Gabriela Guadalupe Elizondo, García-Hernández, Rosa María , Peña, P. García de la, Rojo-Garza, Sandra S., Ruiz Hernandez, Fernando Gerardo , Álvarez‐Villalobos, Neri Alejandro , García-Hernández, Rosa M., Peña, Pablo J. Moreno

Mayo Clinic

Journal of Family Medicine and Primary Care | November 16, 2024 | Volume: 13 | Issue: 11 | Pages: 5002-5008

10.4103/jfmpc.jfmpc_552_24 | PMID 39722964 Get It

A BSTRACT Purpose/Background: To identify the proportion of patients with prediabetes who have prescribed metformin and factors related to doing so as a preventive measure for diabetes in primary care at a Family Medicine Unit in northeastern Mexico. Methods: This retrospective observational study included 372 adults who met the criteria for prediabetes diagnosis according to the American Diabetes Association. Data was collected from medical records from January 2020 to December 2021. Possible associations between the variables of interest and the prescription of metformin were tested via hypothesis tests, furthermore, binary logistic regression was performed. Results: Nearly 85% of the patients met at least one criterion for receiving metformin according to ADA recommendations, but only 60% of them were prescribed this medication. Patients with metformin prescriptions differed from those without in aspects such as having a documented diagnosis of prediabetes in their medical records, a higher BMI, and higher glucose levels. Conclusions: Almost one out of two patients with a high risk of type 2 diabetes are not treated with metformin as a preventive measure. Factors associated with metformin prescription included a high BMI, elevated baseline glucose levels, and a prediabetes diagnosis in the medical record. These findings suggest the need for studies to evaluate physicians’ reasons for different treatments and implementation of recommendations for type 2 diabetes prevention in patients with prediabetes in primary health care.